- $10.05m
- $4.66m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.29 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -89.85% | ||
| Return on Equity | -117.65% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.42 | 2.82 | n/a | 0.65 | n/a | 0.01 | 4.3 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Directors
- Adrian Adams NEC (70)
- Vincent Angotti CEO (53)
- Pamela Palmer CFD (58)
- Raffi Asadorian CFO (51)
- Badri Dasu OTH (58)
- Jill Broadfoot DRC (59)
- Richard Afable IND (67)
- Marina Bozilenko IND (55)
- Mark Edwards IND (63)
- Stephen Hoffman IND (67)
- Howard Rosen IND (63)
- Mark Wan IND (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 13th, 2005
- Public Since
- February 11th, 2011
- No. of Shareholders
- 42
- No. of Employees
- 13
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 20,503,463
- Address
- 1850 Gateway Drive, Suite 175, SAN MATEO, 94404
- Web
- https://talphera.com/
- Phone
- +1 6502163500
- Auditors
- BPM LLP
Upcoming Events for TLPH
Q2 2025 Talphera Inc Earnings Release
Q3 2025 Talphera Inc Earnings Release
Similar to TLPH
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Talphera share price?
As of Today at 23:33 UTC, shares in Talphera are trading at $0.50. This share price information is delayed by 15 minutes.
How has the Talphera share price performed this year?
Shares in Talphera last closed at $0.50 and the price had moved by -56.17% over the past 365 days. In terms of relative price strength the Talphera share price has underperformed the S&P500 Index by -60.99% over the past year.
What are the analyst and broker recommendations for Talphera?
The overall consensus recommendation for Talphera is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Talphera dividend yield?
Talphera does not currently pay a dividend.
Does Talphera pay a dividend?
Talphera does not currently pay a dividend.
When does Talphera next pay dividends?
Talphera does not currently pay a dividend.
How do I buy Talphera shares?
To buy shares in Talphera you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Talphera?
As of the previous close price of $0.50, shares in Talphera had a market capitalisation of $10.33m.
Where are Talphera shares listed?
Here are the trading details for Talphera:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TLPH
What kind of share is Talphera?
Based on an overall assessment of its quality, value and momentum Talphera is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Talphera share price forecast for 2025?
The analyst consensus target price for shares in Talphera is $4.17. That is 727.38% above the last closing price of $0.50.
Analysts covering Talphera currently have a consensus Earnings Per Share (EPS) forecast of -$0.45 for the next financial year.
Find out moreWhat is the trend in the Talphera share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Talphera. Over the past six months, its share price has underperformed the S&P500 Index by -27.76%.
As of the last closing price of $0.50, shares in Talphera were trading -29.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Talphera PE Ratio?
The Talphera PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Talphera?
Talphera's management team is headed by:
- Adrian Adams - NEC
- Vincent Angotti - CEO
- Pamela Palmer - CFD
- Raffi Asadorian - CFO
- Badri Dasu - OTH
- Jill Broadfoot - DRC
- Richard Afable - IND
- Marina Bozilenko - IND
- Mark Edwards - IND
- Stephen Hoffman - IND
- Howard Rosen - IND
- Mark Wan - IND